Erasca, Inc. 2021 Form 10-K Summary
Business context and reporting period
Erasca is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers. The filing covers the fiscal year ended December 31, 2021, including fourth-quarter developments. The company had no approved products, no product revenue, and three clinical-stage programs: ERAS-007, ERAS-601 and ERAS-801. Its broader pipeline comprised 11 wholly owned or controlled programs.
Lead development activities centered on ERAS-007, an oral ERK inhibitor, and ERAS-601, an oral SHP2 inhibitor, which together form the company’s “MAPKlamp” strategy. ERAS-801, a CNS-penetrant EGFR inhibitor, entered clinical development after FDA clearance of its IND in the fourth quarter of 2021.
Financial results, cash flow, liquidity and capital structure
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $73.9 million | $29.6 million | +$44.4 million |
| In-process R&D expense | $10.8 million | $71.7 million | -$60.9 million |
| General and administrative expense | $22.6 million | $8.0 million | +$14.7 million |
| Foundation stock contribution | $17.5 million | $0 | +$17.5 million |
| Total operating expenses | $124.9 million | $109.3 million | +$15.6 million |
| Net loss | $122.8 million | $101.7 million | Loss increased $21.1 million |
| Net loss per share | $1.85 | $4.83 | Improved due primarily to higher share count |
| Cash used in operating activities | $79.6 million | $32.7 million | Use increased $46.9 million |
| Cash used in investing activities | $64.6 million | $71.2 million | Use decreased $6.6 million |
| Cash provided by financing activities | $439.4 million | $140.0 million | +$299.4 million |
No meaningful revenue or operating margin was reported because the company is pre-commercial and generated no product sales. Loss from operations was $124.9 million, compared with $109.3 million in 2020.
Cash, cash equivalents and investments totaled $459.2 million at December 31, 2021, consisting principally of $360.5 million of cash and cash equivalents, $54.0 million of short-term investments and $44.8 million of long-term investments. Total assets were $501.4 million and total liabilities were $44.9 million. The filing does not report outstanding debt; liabilities primarily comprised accounts payable, accrued expenses and operating lease liabilities.
The July 2021 IPO generated $317.0 million of net proceeds. The company also received $119.4 million from the January 2021 Series B-2 preferred stock financing. Management stated that existing cash, cash equivalents and investments were expected to fund operations into 2024, although this estimate is subject to significant assumptions and risks. The company has no committed external source of capital.
Future aggregate operating lease commitments were $87.3 million as of December 31, 2021. Potential development, regulatory and commercial milestone payments and royalties under license agreements are additional contingent obligations whose timing and amount are uncertain.
Material changes versus the prior comparable period
- R&D spending increased 150%, driven by clinical trials, preclinical and discovery activities, personnel growth, outsourced services and stock-based compensation.
- G&A expense increased 184%, reflecting higher headcount, public-company costs, insurance, facilities and professional fees.
- In-process R&D expense fell from $71.7 million to $10.8 million because 2020 included substantial upfront payments related to Asana, NiKang and Katmai, while 2021 primarily reflected UCSF and Emerge Life Sciences transactions.
- The company recorded a $17.5 million stock contribution to the Erasca Foundation, representing 1,093,557 shares issued in connection with the IPO.
- Operating cash burn increased substantially as the company expanded clinical and research activities.
- All outstanding convertible preferred stock converted into 71.3 million common shares at the IPO. Common shares outstanding were 119.1 million at December 31, 2021, compared with 21.9 million at December 31, 2020.
- The company’s clinical pipeline advanced: HERKULES-1 began dosing in May 2021, and HERKULES-2 and HERKULES-3 began dosing in September 2021. FDA cleared the ERAS-801 IND in the fourth quarter of 2021.
Guidance, outlook, commentary and unusual items
- Management expected four product candidates to be in the clinic within the next five quarters and an additional IND filing every 12–18 months through 2026. These are forward-looking plans, not committed milestones.
- Expected clinical readouts included HERKULES-1 monotherapy data and FLAGSHP-1 monotherapy data in the second half of 2022, with additional combination readouts beginning in late 2022 and continuing into 2023.
- ERAS-3490, the company’s CNS-penetrant KRAS G12C program, was nominated as a development candidate in June 2021; the company expected to file an IND in the second half of 2022.
- In February 2022, the company dosed the first patient in the THUNDERBBOLT-1 Phase 1 trial of ERAS-801 in recurrent glioblastoma.
- In March 2022, Erasca Ventures invested $2.0 million in Affini-T Therapeutics, a subsequent event not reflected in 2021 results.
- Preclinical and prior Phase 1 data for ERAS-007 were described as encouraging, including objective responses in selected RAS/MAPK-altered tumors, but the company cautioned that early data may not predict later clinical success.
- Known or emphasized risks include clinical failure, adverse events and class toxicities, combination-treatment tolerability, regulatory delays, patient enrollment, reliance on CROs and third-party manufacturers, competition, intellectual-property challenges, COVID-19 disruptions, cybersecurity, additional financing needs and potential shareholder dilution.
- The company stated that it had not experienced material COVID-19 operating disruption through the filing date, but future effects remained uncertain.
- The company had no material legal proceedings and reported effective disclosure controls at December 31, 2021. It did not provide an auditor attestation of internal control over financial reporting because of the applicable emerging-growth-company transition period.
Most important facts for investors to verify
- Whether the reported cash runway into 2024 remains valid after subsequent clinical expansion, facility commitments, milestone obligations and market conditions.
- Enrollment, safety, dose selection and efficacy data from HERKULES, FLAGSHP-1 and THUNDERBBOLT-1.
- Whether ERAS-007, ERAS-601, ERAS-801 and ERAS-3490 can progress from early-stage development to registrational trials and regulatory approval.
- The amount and timing of contingent milestone payments, royalties and equity issuances under the Asana, NiKang, Katmai, UCSF and other agreements.
- Future operating cash burn, stock-based compensation, dilution from equity financing and the 13.8 million outstanding stock options at year-end.
- Manufacturing capacity, supply redundancy and the company’s dependence on third-party CROs, CMOs and combination-drug suppliers.
- The strength, validity and exclusivity of the company’s owned and licensed patent portfolio, including any diligence or termination conditions in license agreements.
- Competitive clinical results from other RAS/MAPK, KRAS, SHP2, ERK and CNS-targeted oncology programs.